
ðŸŽ¬ æ‰¹é‡è¦–é »å¹»ç‡ˆç‰‡æ•ç²å·¥å…·
============================================================

æœå°‹è¦–é »æ–‡ä»¶...
æ‰¾åˆ° 28 å€‹è¦–é »æ–‡ä»¶:

éœ€è¦è™•ç†: 6 å€‹
å°‡è·³éŽ: 22 å€‹ï¼ˆå·²æœ‰å¹»ç‡ˆç‰‡ï¼‰

å°‡è™•ç†çš„è¦–é »:
  1. Advancing Diabetic Retinopathy Careâ€”Integrating Clinical Insights, AI, and Health Equity.mp4
  2. Diabetic Neuropathyâ€”Unraveling Pain Mechanisms, Systemic Complications, and Innovations in Prevention and Treatment (With ADA Presidents' Select Abstract Presentation).mp4
  3. Innovating Stem Cell Manufacturing and Engraftment Strategies for Cell Replacement Therapy .mp4
  4. Interoceptionâ€”Brainâ€“Body Communication Controls Metabolism .mp4
  5. Mechanisms Linking Adipose Health with Lipid and Glucose Homeostasis .mp4
  6. Metabolic Mediators of Metabolic Wasting.mp4

å°‡è·³éŽçš„è¦–é »ï¼ˆå·²æœ‰å¹»ç‡ˆç‰‡ï¼‰:
  - Advancing Care for Diabetic Kidney Diseaseâ€”Top Research Abstracts  .mp4 (å·²æœ‰ 'Advancing Care for Diabetic Kidney Diseaseâ€”Top Research Abstracts  _slides' æ–‡ä»¶å¤¾)
  - Advancing Effective and Equitable Treatment of Hyperglycemia in Pregnancy.mp4 (å·²æœ‰ 'Advancing Effective and Equitable Treatment of Hyperglycemia in Pregnancy_slides' æ–‡ä»¶å¤¾)
  - Aging and Thrivingâ€”Diabetes, Cognition, and Older Adults .mp4 (å·²æœ‰ 'Aging and Thrivingâ€”Diabetes, Cognition, and Older Adults _slides' æ–‡ä»¶å¤¾)
  - CGM in Actionâ€”Smarter Choices, Better Balance, Lasting Impact.mp4 (å·²æœ‰ 'CGM in Actionâ€”Smarter Choices, Better Balance, Lasting Impact_slides' æ–‡ä»¶å¤¾)
  - Controversies in Peripartum Management of Diabetes .mp4 (å·²æœ‰ 'Controversies in Peripartum Management of Diabetes _slides' æ–‡ä»¶å¤¾)
  - index (1080p_aac).mp4 (å·²æœ‰ 'index (1080p_aac)_slides' æ–‡ä»¶å¤¾)
  - Empowering Choiceâ€”Nutrition Interventions for Type 2 Diabetes.mp4 (å·²æœ‰ 'slides' æ–‡ä»¶å¤¾)
  - Expanding Obesity Therapeutic Optionsâ€”Preclinical Studies .mp4 (å·²æœ‰ 'Expanding Obesity Therapeutic Optionsâ€”Preclinical Studies _slides' æ–‡ä»¶å¤¾)
  - If You Had to Pick Just Oneâ€”GLP-1RA, GIPâ„GLP-1RA or SGLT2i for Type 2 DiabetesÂ¿.mp4 (å·²æœ‰ 'slides' æ–‡ä»¶å¤¾)
  - Improving Systems of Care for Diabetes Mellitus.mp4 (å·²æœ‰ 'Improving Systems of Care for Diabetes Mellitus_slides' æ–‡ä»¶å¤¾)
  - Innovative Solutions to the Challenges of Inpatient Diabetes Care and Educationâ€”From Hospital to Home .mp4 (å·²æœ‰ 'slides' æ–‡ä»¶å¤¾)
  - Itâ€™s Complicatedâ€”Diabetes Profiles, Pathways, and Problems .mp4 (å·²æœ‰ 'Itâ€™s Complicatedâ€”Diabetes Profiles, Pathways, and Problems _slides' æ–‡ä»¶å¤¾)
  - Mechanistic Insights into Metabolic Dysfunction in the Liver .mp4 (å·²æœ‰ 'Mechanistic Insights into Metabolic Dysfunction in the Liver _slides' æ–‡ä»¶å¤¾)
  - Opening a Door to Precision Medicineâ€”Lessons from Human Kidney Tissue in Diabetes.mp4 (å·²æœ‰ 'Opening a Door to Precision Medicineâ€”Lessons from Human Kidney Tissue in Diabetes_slides' æ–‡ä»¶å¤¾)
  - PATHWEIGH Trialâ€”Building the Highway for Weight Management in Primary Care.mp4 (å·²æœ‰ 'PATHWEIGH Trialâ€”Building the Highway for Weight Management in Primary Care_slides' æ–‡ä»¶å¤¾)
  - Ready for Prime TimeÂ¿â€”Pharmacoepidemiology and Real-World Evidence.mp4 (å·²æœ‰ 'Ready for Prime TimeÂ¿â€”Pharmacoepidemiology and Real-World Evidence_slides' æ–‡ä»¶å¤¾)
  - Screening and Primary Prevention Strategies for ASCVD in Diabetes.mp4 (å·²æœ‰ 'Screening and Primary Prevention Strategies for ASCVD in Diabetes_slides' æ–‡ä»¶å¤¾)
  - index (1080p_aac).mp4 (å·²æœ‰ 'index (1080p_aac)_slides' æ–‡ä»¶å¤¾)
  - The Future of Weight Loss Therapiesâ€”Food Intake Versus Energy Expenditure.mp4 (å·²æœ‰ 'The Future of Weight Loss Therapiesâ€”Food Intake Versus Energy Expenditure_slides' æ–‡ä»¶å¤¾)
  - Timing Is Everythingâ€”Circadian Rhythms in Health and Disease .mp4 (å·²æœ‰ 'Timing Is Everythingâ€”Circadian Rhythms in Health and Disease _slides' æ–‡ä»¶å¤¾)
  - Unraveling the Secrets of Energy, Appetite, and Sugar Control .mp4 (å·²æœ‰ 'Unraveling the Secrets of Energy, Appetite, and Sugar Control _slides' æ–‡ä»¶å¤¾)
  - What Is the Real Molecular Target(s) of Metformin.mp4 (å·²æœ‰ 'What Is the Real Molecular Target(s) of Metformin_slides' æ–‡ä»¶å¤¾)

é€²åº¦: 1/28

============================================================
è™•ç†è¦–é »: Advancing Care for Diabetic Kidney Diseaseâ€”Top Research Abstracts  .mp4
è·¯å¾‘: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Advancing Care for Diabetic Kidney Diseaseâ€”Top Research Abstracts /Advancing Care for Diabetic Kidney Diseaseâ€”Top Research Abstracts/Advancing Care for Diabetic Kidney Diseaseâ€”Top Research Abstracts  .mp4
============================================================
âš ï¸  å·²å­˜åœ¨å¹»ç‡ˆç‰‡æ–‡ä»¶å¤¾ 'Advancing Care for Diabetic Kidney Diseaseâ€”Top Research Abstracts  _slides'ï¼Œè·³éŽè™•ç†

é€²åº¦: 2/28

============================================================
è™•ç†è¦–é »: Advancing Diabetic Retinopathy Careâ€”Integrating Clinical Insights, AI, and Health Equity.mp4
è·¯å¾‘: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Advancing Diabetic Retinopathy Careâ€”Integrating Clinical Insights, AI, and Health Equity/Advancing Diabetic Retinopathy Careâ€”Integrating Clinical Insights, AI, and Health Equity/Advancing Diabetic Retinopathy Careâ€”Integrating Clinical Insights, AI, and Health Equity.mp4
============================================================
ä½¿ç”¨é€²éšŽæ¨¡å¼æ•ç²å¹»ç‡ˆç‰‡...
ç›¸ä¼¼åº¦é–¾å€¼: 0.8
åˆ†çµ„é–¾å€¼: 0.88
é–‹å§‹åˆ†æžè¦–é »ï¼š/Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Advancing Diabetic Retinopathy Careâ€”Integrating Clinical Insights, AI, and Health Equity/Advancing Diabetic Retinopathy Careâ€”Integrating Clinical Insights, AI, and Health Equity/Advancing Diabetic Retinopathy Careâ€”Integrating Clinical Insights, AI, and Health Equity.mp4
ç¸½å¹€æ•¸ï¼š78570, FPSï¼š30.0
ç›¸ä¼¼åº¦é–¾å€¼ï¼š0.8, åˆ†çµ„é–¾å€¼ï¼š0.88

ç¬¬ä¸€éï¼šå¿«é€ŸæŽƒæ...
å¿«é€ŸæŽƒæé€²åº¦ï¼š0.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š0.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š1.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š2.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š3.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š3.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š4.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š5.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š6.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š6.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š7.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š8.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š9.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š9.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š10.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š11.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š12.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š13.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š13.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š14.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š15.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š16.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š16.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š17.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š18.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š19.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š19.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š20.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š21.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š22.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š22.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š23.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š24.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š25.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š26.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š26.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š27.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š28.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š29.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š29.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š30.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š31.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š32.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š32.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š33.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š34.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š35.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š35.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š36.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š37.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š38.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š38.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š39.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š40.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š41.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š42.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š42.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š43.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š44.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š45.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š45.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š46.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š47.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š48.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š48.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š49.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š50.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š51.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š51.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š52.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š53.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š54.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š55.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š55.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š56.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š57.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š58.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š58.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š59.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š60.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š61.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š61.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š62.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š63.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š64.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š64.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š65.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š66.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š67.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š68.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š68.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š69.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š70.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š71.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š71.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š72.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š73.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š74.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š74.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š75.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š76.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š77.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š77.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š78.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š79.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š80.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š80.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š81.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š82.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š83.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š84.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š84.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š85.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š86.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š87.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š87.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š88.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š89.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š90.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š90.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š91.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š92.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š93.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š93.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š94.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š95.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š96.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š97.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š97.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š98.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š99.3%

ç¬¬äºŒéï¼šç²¾ç¢ºæª¢æ¸¬ 181 å€‹å€™é¸é»ž...
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š0.0%
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š27.6%
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š55.2%
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š82.9%

ç¬¬ä¸‰éï¼šåˆ†çµ„å’ŒåŽ»é‡...

ä¿å­˜ 12 å¼µå¹»ç‡ˆç‰‡...
ä¿å­˜å¹»ç‡ˆç‰‡ 1/12: slide_g01_t33.0s_f88c47d3.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 2/12: slide_g02_t1013.0s_fb80902f.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 3/12: slide_g03_t1013.8s_8585fd7f.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 4/12: slide_g04_t1031.7s_d53daad0.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 5/12: slide_g05_t1581.0s_ab87c6b0.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 6/12: slide_g06_t1889.8s_fab8c7e4.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 7/12: slide_g07_t1943.0s_afc8d031.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 8/12: slide_g08_t1969.5s_f994c461.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 9/12: slide_g09_t2083.0s_96f2b950.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 10/12: slide_g10_t2101.8s_bb3b2b81.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 11/12: slide_g11_t2413.0s_af91d84c.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 12/12: slide_g12_t2414.0s_b3b91464.jpg

å…ƒæ•¸æ“šå·²ä¿å­˜åˆ°: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Advancing Diabetic Retinopathy Careâ€”Integrating Clinical Insights, AI, and Health Equity/Advancing Diabetic Retinopathy Careâ€”Integrating Clinical Insights, AI, and Health Equity/Advancing Diabetic Retinopathy Careâ€”Integrating Clinical Insights, AI, and Health Equity_slides/slides_metadata.json

âœ… æ•ç²æˆåŠŸï¼
   å¹»ç‡ˆç‰‡æ•¸: 12
   åˆ†çµ„æ•¸: 12
   è€—æ™‚: 205.9 ç§’
   è¼¸å‡º: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Advancing Diabetic Retinopathy Careâ€”Integrating Clinical Insights, AI, and Health Equity/Advancing Diabetic Retinopathy Careâ€”Integrating Clinical Insights, AI, and Health Equity/Advancing Diabetic Retinopathy Careâ€”Integrating Clinical Insights, AI, and Health Equity_slides

ç”Ÿæˆ HTML é è¦½...
   é è¦½å·²ç”Ÿæˆ: preview.html

é€²åº¦: 3/28

============================================================
è™•ç†è¦–é »: Advancing Effective and Equitable Treatment of Hyperglycemia in Pregnancy.mp4
è·¯å¾‘: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Advancing Effective and Equitable Treatment of Hyperglycemia in Pregnancy/Advancing Effective and Equitable Treatment of Hyperglycemia in Pregnancy/Advancing Effective and Equitable Treatment of Hyperglycemia in Pregnancy.mp4
============================================================
âš ï¸  å·²å­˜åœ¨å¹»ç‡ˆç‰‡æ–‡ä»¶å¤¾ 'Advancing Effective and Equitable Treatment of Hyperglycemia in Pregnancy_slides'ï¼Œè·³éŽè™•ç†

é€²åº¦: 4/28

============================================================
è™•ç†è¦–é »: Aging and Thrivingâ€”Diabetes, Cognition, and Older Adults .mp4
è·¯å¾‘: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Aging and Thrivingâ€”Diabetes, Cognition, and Older Adults /Aging and Thrivingâ€”Diabetes, Cognition, and Older Adults/Aging and Thrivingâ€”Diabetes, Cognition, and Older Adults .mp4
============================================================
âš ï¸  å·²å­˜åœ¨å¹»ç‡ˆç‰‡æ–‡ä»¶å¤¾ 'Aging and Thrivingâ€”Diabetes, Cognition, and Older Adults _slides'ï¼Œè·³éŽè™•ç†

é€²åº¦: 5/28

============================================================
è™•ç†è¦–é »: CGM in Actionâ€”Smarter Choices, Better Balance, Lasting Impact.mp4
è·¯å¾‘: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/CGM in Actionâ€”Smarter Choices, Better Balance, Lasting Impact/CGM in Actionâ€”Smarter Choices, Better Balance, Lasting Impact.mp4
============================================================
âš ï¸  å·²å­˜åœ¨å¹»ç‡ˆç‰‡æ–‡ä»¶å¤¾ 'CGM in Actionâ€”Smarter Choices, Better Balance, Lasting Impact_slides'ï¼Œè·³éŽè™•ç†

é€²åº¦: 6/28

============================================================
è™•ç†è¦–é »: Controversies in Peripartum Management of Diabetes .mp4
è·¯å¾‘: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Controversies in Peripartum Management of Diabetes /Controversies in Peripartum Management of Diabetes/Controversies in Peripartum Management of Diabetes .mp4
============================================================
âš ï¸  å·²å­˜åœ¨å¹»ç‡ˆç‰‡æ–‡ä»¶å¤¾ 'Controversies in Peripartum Management of Diabetes _slides'ï¼Œè·³éŽè™•ç†

é€²åº¦: 7/28

============================================================
è™•ç†è¦–é »: index (1080p_aac).mp4
è·¯å¾‘: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Diabetes in Childrenâ€”Pediatric Type 1 Diabetesâ€”Decoding the Disease and Transforming Care/index (1080p_aac)/index (1080p_aac).mp4
============================================================
âš ï¸  å·²å­˜åœ¨å¹»ç‡ˆç‰‡æ–‡ä»¶å¤¾ 'index (1080p_aac)_slides'ï¼Œè·³éŽè™•ç†

é€²åº¦: 8/28

============================================================
è™•ç†è¦–é »: Diabetic Neuropathyâ€”Unraveling Pain Mechanisms, Systemic Complications, and Innovations in Prevention and Treatment (With ADA Presidents' Select Abstract Presentation).mp4
è·¯å¾‘: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Diabetic Neuropathyâ€”Unraveling Pain Mechanisms, Systemic Complications, and Innovations in Prevention and Treatment (With ADA Presidents' Select Abstract Presentation)/Diabetic Neuropathyâ€”Unraveling Pain Mechanisms, Systemic Complications, and Innovations in Prevention and Treatment (With ADA Presidents' Select Abstract Presentation)/Diabetic Neuropathyâ€”Unraveling Pain Mechanisms, Systemic Complications, and Innovations in Prevention and Treatment (With ADA Presidents' Select Abstract Presentation).mp4
============================================================
ä½¿ç”¨é€²éšŽæ¨¡å¼æ•ç²å¹»ç‡ˆç‰‡...
ç›¸ä¼¼åº¦é–¾å€¼: 0.8
åˆ†çµ„é–¾å€¼: 0.88
é–‹å§‹åˆ†æžè¦–é »ï¼š/Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Diabetic Neuropathyâ€”Unraveling Pain Mechanisms, Systemic Complications, and Innovations in Prevention and Treatment (With ADA Presidents' Select Abstract Presentation)/Diabetic Neuropathyâ€”Unraveling Pain Mechanisms, Systemic Complications, and Innovations in Prevention and Treatment (With ADA Presidents' Select Abstract Presentation)/Diabetic Neuropathyâ€”Unraveling Pain Mechanisms, Systemic Complications, and Innovations in Prevention and Treatment (With ADA Presidents' Select Abstract Presentation).mp4
ç¸½å¹€æ•¸ï¼š109363, FPSï¼š30.0
ç›¸ä¼¼åº¦é–¾å€¼ï¼š0.8, åˆ†çµ„é–¾å€¼ï¼š0.88

ç¬¬ä¸€éï¼šå¿«é€ŸæŽƒæ...
å¿«é€ŸæŽƒæé€²åº¦ï¼š0.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š0.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š1.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š1.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š2.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š2.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š3.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š3.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š4.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š4.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š5.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š6.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š6.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š7.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š7.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š8.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š8.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š9.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š9.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š10.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š11.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š11.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š12.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š12.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š13.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š13.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š14.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š14.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š15.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š15.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š16.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š17.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š17.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š18.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š18.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š19.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š19.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š20.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š20.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š21.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š21.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š22.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š23.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š23.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š24.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š24.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š25.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š25.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š26.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š26.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š27.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š28.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š28.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š29.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š29.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š30.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š30.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š31.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š31.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š32.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š32.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š33.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š34.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š34.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š35.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š35.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š36.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š36.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š37.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š37.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š38.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š39.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š39.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š40.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š40.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š41.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š41.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š42.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š42.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š43.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š43.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š44.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š45.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š45.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š46.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š46.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š47.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š47.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š48.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š48.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š49.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š49.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š50.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š51.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š51.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š52.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š52.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š53.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š53.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š54.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š54.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š55.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š56.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š56.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š57.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š57.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š58.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š58.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š59.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š59.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š60.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š60.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š61.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š62.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š62.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š63.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š63.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š64.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š64.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š65.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š65.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š66.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š66.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š67.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š68.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š68.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š69.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š69.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š70.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š70.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š71.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š71.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š72.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š73.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š73.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š74.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š74.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š75.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š75.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š76.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š76.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š77.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š77.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š78.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š79.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š79.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š80.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š80.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š81.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š81.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š82.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š82.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š83.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š83.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š84.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š85.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š85.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š86.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š86.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š87.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š87.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š88.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š88.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š89.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š90.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š90.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š91.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š91.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š92.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š92.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š93.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š93.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š94.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š94.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š95.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š96.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š96.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š97.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š97.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š98.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š98.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š99.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š99.9%

ç¬¬äºŒéï¼šç²¾ç¢ºæª¢æ¸¬ 478 å€‹å€™é¸é»ž...
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š0.0%
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š10.5%
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š20.9%
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š31.4%
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š41.8%
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š52.3%
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š62.8%
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š73.2%
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š83.7%
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š94.1%

ç¬¬ä¸‰éï¼šåˆ†çµ„å’ŒåŽ»é‡...

ä¿å­˜ 41 å¼µå¹»ç‡ˆç‰‡...
ä¿å­˜å¹»ç‡ˆç‰‡ 1/41: slide_g01_t13.0s_daa1a5aa.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 2/41: slide_g02_t21.0s_e8a44529.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 3/41: slide_g03_t29.5s_a788d027.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 4/41: slide_g04_t37.8s_97e8108f.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 5/41: slide_g05_t55.0s_dac8b1ad.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 6/41: slide_g06_t63.0s_d3cc94a3.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 7/41: slide_g07_t73.0s_deca24c1.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 8/41: slide_g08_t73.7s_80000000.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 9/41: slide_g09_t75.2s_caa5ca05.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 10/41: slide_g10_t87.8s_bfe46837.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 11/41: slide_g11_t363.0s_ba0fc481.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 12/41: slide_g12_t403.0s_9f42c081.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 13/41: slide_g13_t403.7s_b18e8630.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 14/41: slide_g14_t425.0s_e8999646.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 15/41: slide_g15_t451.0s_bfed4d38.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 16/41: slide_g16_t625.0s_af07848c.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 17/41: slide_g17_t625.8s_da351a99.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 18/41: slide_g18_t630.0s_85c5d57f.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 19/41: slide_g19_t821.0s_b331cc27.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 20/41: slide_g20_t845.5s_8f297029.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 21/41: slide_g21_t1197.0s_bf2f2b2f.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 22/41: slide_g22_t1249.0s_bb2f2f6f.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 23/41: slide_g23_t1369.0s_af2f2d2b.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 24/41: slide_g24_t1369.7s_af38682f.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 25/41: slide_g25_t1667.0s_ed2b2b6b.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 26/41: slide_g26_t1693.8s_b911261b.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 27/41: slide_g27_t2149.0s_b8d427d3.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 28/41: slide_g28_t2229.0s_fa53e7ad.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 29/41: slide_g29_t2229.7s_a9f831e8.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 30/41: slide_g30_t2275.0s_abfc61f8.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 31/41: slide_g31_t2355.0s_8fb422b0.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 32/41: slide_g32_t2355.7s_aeb54ab1.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 33/41: slide_g33_t2357.0s_ba6a4e4a.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 34/41: slide_g34_t2835.0s_a3e2c427.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 35/41: slide_g35_t2847.0s_c0332f3e.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 36/41: slide_g36_t2891.0s_e665c99a.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 37/41: slide_g37_t3237.0s_a7c020df.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 38/41: slide_g38_t3237.7s_e47237c5.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 39/41: slide_g39_t3283.7s_8fa7f8e9.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 40/41: slide_g40_t3341.0s_f0698649.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 41/41: slide_g41_t3437.0s_bd8ecbc3.jpg

å…ƒæ•¸æ“šå·²ä¿å­˜åˆ°: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Diabetic Neuropathyâ€”Unraveling Pain Mechanisms, Systemic Complications, and Innovations in Prevention and Treatment (With ADA Presidents' Select Abstract Presentation)/Diabetic Neuropathyâ€”Unraveling Pain Mechanisms, Systemic Complications, and Innovations in Prevention and Treatment (With ADA Presidents' Select Abstract Presentation)/Diabetic Neuropathyâ€”Unraveling Pain Mechanisms, Systemic Complications, and Innovations in Prevention and Treatment (With ADA Presidents' Select Abstract Presentation)_slides/slides_metadata.json

âœ… æ•ç²æˆåŠŸï¼
   å¹»ç‡ˆç‰‡æ•¸: 41
   åˆ†çµ„æ•¸: 41
   è€—æ™‚: 166.5 ç§’
   è¼¸å‡º: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Diabetic Neuropathyâ€”Unraveling Pain Mechanisms, Systemic Complications, and Innovations in Prevention and Treatment (With ADA Presidents' Select Abstract Presentation)/Diabetic Neuropathyâ€”Unraveling Pain Mechanisms, Systemic Complications, and Innovations in Prevention and Treatment (With ADA Presidents' Select Abstract Presentation)/Diabetic Neuropathyâ€”Unraveling Pain Mechanisms, Systemic Complications, and Innovations in Prevention and Treatment (With ADA Presidents' Select Abstract Presentation)_slides

ç”Ÿæˆ HTML é è¦½...
   é è¦½å·²ç”Ÿæˆ: preview.html

é€²åº¦: 9/28

============================================================
è™•ç†è¦–é »: Empowering Choiceâ€”Nutrition Interventions for Type 2 Diabetes.mp4
è·¯å¾‘: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Empowering Choiceâ€”Nutrition Interventions for Type 2 Diabetes/Empowering Choiceâ€”Nutrition Interventions for Type 2 Diabetes.mp4
============================================================
âš ï¸  å·²å­˜åœ¨å¹»ç‡ˆç‰‡æ–‡ä»¶å¤¾ 'slides'ï¼Œè·³éŽè™•ç†

é€²åº¦: 10/28

============================================================
è™•ç†è¦–é »: Expanding Obesity Therapeutic Optionsâ€”Preclinical Studies .mp4
è·¯å¾‘: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Expanding Obesity Therapeutic Optionsâ€”Preclinical Studies /Expanding Obesity Therapeutic Optionsâ€”Preclinical Studies/Expanding Obesity Therapeutic Optionsâ€”Preclinical Studies .mp4
============================================================
âš ï¸  å·²å­˜åœ¨å¹»ç‡ˆç‰‡æ–‡ä»¶å¤¾ 'Expanding Obesity Therapeutic Optionsâ€”Preclinical Studies _slides'ï¼Œè·³éŽè™•ç†

é€²åº¦: 11/28

============================================================
è™•ç†è¦–é »: If You Had to Pick Just Oneâ€”GLP-1RA, GIPâ„GLP-1RA or SGLT2i for Type 2 DiabetesÂ¿.mp4
è·¯å¾‘: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/If You Had to Pick Just Oneâ€”GLP-1RA, GIP:GLP-1RA or SGLT2i for Type 2 Diabetes?/If You Had to Pick Just Oneâ€”GLP-1RA, GIPâ„GLP-1RA or SGLT2i for Type 2 DiabetesÂ¿.mp4
============================================================
âš ï¸  å·²å­˜åœ¨å¹»ç‡ˆç‰‡æ–‡ä»¶å¤¾ 'slides'ï¼Œè·³éŽè™•ç†

é€²åº¦: 12/28

============================================================
è™•ç†è¦–é »: Improving Systems of Care for Diabetes Mellitus.mp4
è·¯å¾‘: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Improving Systems of Care for Diabetes Mellitus/Improving Systems of Care for Diabetes Mellitus.mp4
============================================================
âš ï¸  å·²å­˜åœ¨å¹»ç‡ˆç‰‡æ–‡ä»¶å¤¾ 'Improving Systems of Care for Diabetes Mellitus_slides'ï¼Œè·³éŽè™•ç†

é€²åº¦: 13/28

============================================================
è™•ç†è¦–é »: Innovating Stem Cell Manufacturing and Engraftment Strategies for Cell Replacement Therapy .mp4
è·¯å¾‘: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Innovating Stem Cell Manufacturing and Engraftment Strategies for Cell Replacement Therapy/Innovating Stem Cell Manufacturing and Engraftment Strategies for Cell Replacement Therapy/Innovating Stem Cell Manufacturing and Engraftment Strategies for Cell Replacement Therapy .mp4
============================================================
ä½¿ç”¨é€²éšŽæ¨¡å¼æ•ç²å¹»ç‡ˆç‰‡...
ç›¸ä¼¼åº¦é–¾å€¼: 0.8
åˆ†çµ„é–¾å€¼: 0.88
é–‹å§‹åˆ†æžè¦–é »ï¼š/Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Innovating Stem Cell Manufacturing and Engraftment Strategies for Cell Replacement Therapy/Innovating Stem Cell Manufacturing and Engraftment Strategies for Cell Replacement Therapy/Innovating Stem Cell Manufacturing and Engraftment Strategies for Cell Replacement Therapy .mp4
ç¸½å¹€æ•¸ï¼š44317, FPSï¼š30.0
ç›¸ä¼¼åº¦é–¾å€¼ï¼š0.8, åˆ†çµ„é–¾å€¼ï¼š0.88

ç¬¬ä¸€éï¼šå¿«é€ŸæŽƒæ...
å¿«é€ŸæŽƒæé€²åº¦ï¼š0.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š1.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š2.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š4.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š5.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š6.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š8.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š9.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š10.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š12.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š13.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š14.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š16.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š17.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š19.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š20.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š21.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š23.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š24.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š25.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š27.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š28.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š29.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š31.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š32.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š33.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š35.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š36.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š37.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š39.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š40.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š42.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š43.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š44.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š46.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š47.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š48.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š50.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š51.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š52.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š54.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š55.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š56.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š58.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š59.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š60.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š62.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š63.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š65.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š66.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š67.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š69.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š70.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š71.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š73.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š74.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š75.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š77.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š78.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š79.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š81.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š82.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š83.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š85.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š86.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š88.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š89.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š90.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š92.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š93.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š94.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š96.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š97.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š98.8%

ç¬¬äºŒéï¼šç²¾ç¢ºæª¢æ¸¬ 39 å€‹å€™é¸é»ž...
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š0.0%

ç¬¬ä¸‰éï¼šåˆ†çµ„å’ŒåŽ»é‡...

ä¿å­˜ 4 å¼µå¹»ç‡ˆç‰‡...
ä¿å­˜å¹»ç‡ˆç‰‡ 1/4: slide_g01_t21.0s_f0b1ce8e.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 2/4: slide_g02_t21.7s_c9b64bcb.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 3/4: slide_g03_t77.0s_a6319966.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 4/4: slide_g04_t1183.0s_c4c4bf3b.jpg

å…ƒæ•¸æ“šå·²ä¿å­˜åˆ°: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Innovating Stem Cell Manufacturing and Engraftment Strategies for Cell Replacement Therapy/Innovating Stem Cell Manufacturing and Engraftment Strategies for Cell Replacement Therapy/Innovating Stem Cell Manufacturing and Engraftment Strategies for Cell Replacement Therapy _slides/slides_metadata.json

âœ… æ•ç²æˆåŠŸï¼
   å¹»ç‡ˆç‰‡æ•¸: 4
   åˆ†çµ„æ•¸: 4
   è€—æ™‚: 35.1 ç§’
   è¼¸å‡º: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Innovating Stem Cell Manufacturing and Engraftment Strategies for Cell Replacement Therapy/Innovating Stem Cell Manufacturing and Engraftment Strategies for Cell Replacement Therapy/Innovating Stem Cell Manufacturing and Engraftment Strategies for Cell Replacement Therapy _slides

ç”Ÿæˆ HTML é è¦½...
   é è¦½å·²ç”Ÿæˆ: preview.html

é€²åº¦: 14/28

============================================================
è™•ç†è¦–é »: Innovative Solutions to the Challenges of Inpatient Diabetes Care and Educationâ€”From Hospital to Home .mp4
è·¯å¾‘: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Innovative Solutions to the Challenges of Inpatient Diabetes Care and Educationâ€”From Hospital to Home /Innovative Solutions to the Challenges of Inpatient Diabetes Care and Educationâ€”From Hospital to Home/Innovative Solutions to the Challenges of Inpatient Diabetes Care and Educationâ€”From Hospital to Home .mp4
============================================================
âš ï¸  å·²å­˜åœ¨å¹»ç‡ˆç‰‡æ–‡ä»¶å¤¾ 'slides'ï¼Œè·³éŽè™•ç†

é€²åº¦: 15/28

============================================================
è™•ç†è¦–é »: Interoceptionâ€”Brainâ€“Body Communication Controls Metabolism .mp4
è·¯å¾‘: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Interoceptionâ€”Brainâ€“Body Communication Controls Metabolism/Interoceptionâ€”Brainâ€“Body Communication Controls Metabolism/Interoceptionâ€”Brainâ€“Body Communication Controls Metabolism .mp4
============================================================
ä½¿ç”¨é€²éšŽæ¨¡å¼æ•ç²å¹»ç‡ˆç‰‡...
ç›¸ä¼¼åº¦é–¾å€¼: 0.8
åˆ†çµ„é–¾å€¼: 0.88
é–‹å§‹åˆ†æžè¦–é »ï¼š/Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Interoceptionâ€”Brainâ€“Body Communication Controls Metabolism/Interoceptionâ€”Brainâ€“Body Communication Controls Metabolism/Interoceptionâ€”Brainâ€“Body Communication Controls Metabolism .mp4
ç¸½å¹€æ•¸ï¼š157379, FPSï¼š30.0
ç›¸ä¼¼åº¦é–¾å€¼ï¼š0.8, åˆ†çµ„é–¾å€¼ï¼š0.88

ç¬¬ä¸€éï¼šå¿«é€ŸæŽƒæ...
å¿«é€ŸæŽƒæé€²åº¦ï¼š0.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š0.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š0.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š1.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š1.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š1.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š2.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š2.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š3.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š3.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š3.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š4.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š4.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š5.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š5.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š5.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š6.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š6.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š6.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š7.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š7.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š8.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š8.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š8.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š9.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š9.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š9.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š10.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š10.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š11.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š11.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š11.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š12.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š12.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š13.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š13.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š13.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š14.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š14.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š14.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š15.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š15.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š16.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š16.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š16.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š17.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š17.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š17.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š18.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š18.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š19.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š19.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š19.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š20.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š20.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š21.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š21.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š21.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š22.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š22.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š22.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š23.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š23.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š24.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š24.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š24.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š25.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š25.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š25.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š26.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š26.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š27.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š27.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š27.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š28.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š28.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š29.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š29.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š29.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š30.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š30.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š30.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š31.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š31.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š32.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š32.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š32.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š33.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š33.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š33.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š34.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š34.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š35.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š35.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š35.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š36.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š36.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š37.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š37.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š37.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š38.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š38.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š38.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š39.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š39.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š40.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š40.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š40.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š41.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š41.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š41.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š42.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š42.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š43.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š43.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š43.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š44.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š44.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š45.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š45.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š45.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š46.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š46.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š46.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š47.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š47.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š48.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š48.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š48.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š49.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š49.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š49.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š50.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š50.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š51.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š51.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š51.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š52.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š52.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š53.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š53.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š53.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š54.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š54.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š54.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š55.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š55.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š56.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š56.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š56.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š57.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š57.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š57.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š58.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š58.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š59.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š59.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š59.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š60.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š60.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š61.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š61.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š61.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š62.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š62.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š62.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š63.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š63.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š64.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š64.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š64.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š65.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š65.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š66.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š66.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š66.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š67.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š67.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š67.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š68.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š68.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š69.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š69.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š69.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š70.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š70.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š70.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š71.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š71.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š72.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š72.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š72.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š73.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š73.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š74.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š74.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š74.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š75.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š75.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š75.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š76.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š76.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š77.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š77.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š77.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š78.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š78.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š78.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š79.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š79.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š80.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š80.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š80.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š81.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š81.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š82.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š82.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š82.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š83.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š83.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š83.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š84.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š84.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š85.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š85.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š85.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š86.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š86.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š86.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š87.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š87.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š88.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š88.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š88.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š89.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š89.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š90.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š90.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š90.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š91.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š91.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š91.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š92.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š92.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š93.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š93.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š93.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š94.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š94.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š94.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š95.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š95.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š96.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š96.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š96.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š97.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š97.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š98.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š98.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š98.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š99.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š99.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š99.9%

ç¬¬äºŒéï¼šç²¾ç¢ºæª¢æ¸¬ 284 å€‹å€™é¸é»ž...
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š0.0%
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š17.6%
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š35.2%
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š52.8%
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š70.4%
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š88.0%

ç¬¬ä¸‰éï¼šåˆ†çµ„å’ŒåŽ»é‡...

ä¿å­˜ 23 å¼µå¹»ç‡ˆç‰‡...
ä¿å­˜å¹»ç‡ˆç‰‡ 1/23: slide_g01_t1233.0s_c4c4bb3b.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 2/23: slide_g02_t1253.0s_c5b7699f.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 3/23: slide_g03_t1291.0s_d177c6ff.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 4/23: slide_g04_t2373.0s_d5f77eff.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 5/23: slide_g05_t2375.5s_905be825.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 6/23: slide_g06_t2383.8s_a9a95456.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 7/23: slide_g07_t2469.0s_ea133565.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 8/23: slide_g08_t2561.0s_af38c212.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 9/23: slide_g09_t2583.0s_ea2c3d39.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 10/23: slide_g10_t2775.0s_a0d1b1d3.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 11/23: slide_g11_t2887.0s_b891674e.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 12/23: slide_g12_t2887.7s_ef0f9d68.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 13/23: slide_g13_t2943.0s_ada1d2d0.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 14/23: slide_g14_t2957.0s_ab2b2b2b.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 15/23: slide_g15_t3117.0s_bbc4c43f.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 16/23: slide_g16_t3117.8s_efa8c011.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 17/23: slide_g17_t3135.3s_f8696f6e.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 18/23: slide_g18_t3449.0s_b9191731.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 19/23: slide_g19_t3539.7s_e7659198.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 20/23: slide_g20_t3577.0s_fda2419b.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 21/23: slide_g21_t3591.7s_d7ab52a9.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 22/23: slide_g22_t3593.7s_ac299304.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 23/23: slide_g23_t4545.0s_e08f3045.jpg

å…ƒæ•¸æ“šå·²ä¿å­˜åˆ°: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Interoceptionâ€”Brainâ€“Body Communication Controls Metabolism/Interoceptionâ€”Brainâ€“Body Communication Controls Metabolism/Interoceptionâ€”Brainâ€“Body Communication Controls Metabolism _slides/slides_metadata.json

âœ… æ•ç²æˆåŠŸï¼
   å¹»ç‡ˆç‰‡æ•¸: 23
   åˆ†çµ„æ•¸: 23
   è€—æ™‚: 129.8 ç§’
   è¼¸å‡º: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Interoceptionâ€”Brainâ€“Body Communication Controls Metabolism/Interoceptionâ€”Brainâ€“Body Communication Controls Metabolism/Interoceptionâ€”Brainâ€“Body Communication Controls Metabolism _slides

ç”Ÿæˆ HTML é è¦½...
   é è¦½å·²ç”Ÿæˆ: preview.html

é€²åº¦: 16/28

============================================================
è™•ç†è¦–é »: Itâ€™s Complicatedâ€”Diabetes Profiles, Pathways, and Problems .mp4
è·¯å¾‘: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Itâ€™s Complicatedâ€”Diabetes Profiles, Pathways, and Problems /Itâ€™s Complicatedâ€”Diabetes Profiles, Pathways, and Problems/Itâ€™s Complicatedâ€”Diabetes Profiles, Pathways, and Problems .mp4
============================================================
âš ï¸  å·²å­˜åœ¨å¹»ç‡ˆç‰‡æ–‡ä»¶å¤¾ 'Itâ€™s Complicatedâ€”Diabetes Profiles, Pathways, and Problems _slides'ï¼Œè·³éŽè™•ç†

é€²åº¦: 17/28

============================================================
è™•ç†è¦–é »: Mechanisms Linking Adipose Health with Lipid and Glucose Homeostasis .mp4
è·¯å¾‘: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Mechanisms Linking Adipose Health with Lipid and Glucose Homeostasis/Mechanisms Linking Adipose Health with Lipid and Glucose Homeostasis/Mechanisms Linking Adipose Health with Lipid and Glucose Homeostasis .mp4
============================================================
ä½¿ç”¨é€²éšŽæ¨¡å¼æ•ç²å¹»ç‡ˆç‰‡...
ç›¸ä¼¼åº¦é–¾å€¼: 0.8
åˆ†çµ„é–¾å€¼: 0.88
é–‹å§‹åˆ†æžè¦–é »ï¼š/Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Mechanisms Linking Adipose Health with Lipid and Glucose Homeostasis/Mechanisms Linking Adipose Health with Lipid and Glucose Homeostasis/Mechanisms Linking Adipose Health with Lipid and Glucose Homeostasis .mp4
ç¸½å¹€æ•¸ï¼š67244, FPSï¼š30.0
ç›¸ä¼¼åº¦é–¾å€¼ï¼š0.8, åˆ†çµ„é–¾å€¼ï¼š0.88

ç¬¬ä¸€éï¼šå¿«é€ŸæŽƒæ...
å¿«é€ŸæŽƒæé€²åº¦ï¼š0.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š0.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š1.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š2.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š3.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š4.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š5.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š6.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š7.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š8.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š8.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š9.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š10.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š11.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š12.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š13.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š14.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š15.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š16.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š17.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š17.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š18.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š19.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š20.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š21.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š22.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š23.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š24.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š25.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š25.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š26.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š27.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š28.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š29.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š30.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š31.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š32.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š33.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š33.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š34.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š35.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š36.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š37.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š38.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š39.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š40.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š41.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š41.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š42.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š43.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š44.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š45.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š46.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š47.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š48.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š49.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š50.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š50.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š51.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š52.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š53.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š54.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š55.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š56.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š57.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š58.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š58.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š59.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š60.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š61.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š62.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š63.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š64.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š65.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š66.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š66.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š67.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š68.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š69.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š70.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š71.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š72.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š73.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š74.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š75.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š75.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š76.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š77.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š78.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š79.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š80.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š81.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š82.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š83.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š83.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š84.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š85.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š86.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š87.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š88.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š89.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š90.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š91.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š91.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š92.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š93.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š94.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š95.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š96.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š97.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š98.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š99.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š99.9%

ç¬¬äºŒéï¼šç²¾ç¢ºæª¢æ¸¬ 182 å€‹å€™é¸é»ž...
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š0.0%
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š27.5%
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š54.9%
ç²¾ç¢ºæª¢æ¸¬é€²åº¦ï¼š82.4%

ç¬¬ä¸‰éï¼šåˆ†çµ„å’ŒåŽ»é‡...

ä¿å­˜ 16 å¼µå¹»ç‡ˆç‰‡...
ä¿å­˜å¹»ç‡ˆç‰‡ 1/16: slide_g01_t57.0s_b327eccc.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 2/16: slide_g02_t67.3s_e5211899.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 3/16: slide_g03_t189.0s_a60dd8f2.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 4/16: slide_g04_t212.0s_bf3cd29b.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 5/16: slide_g05_t241.5s_a2669411.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 6/16: slide_g06_t251.7s_bf3cd29a.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 7/16: slide_g07_t257.3s_971ddd87.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 8/16: slide_g08_t591.0s_9e1f1b3d.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 9/16: slide_g09_t591.8s_9011fabc.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 10/16: slide_g10_t619.0s_ea169469.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 11/16: slide_g11_t975.0s_c94b96b0.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 12/16: slide_g12_t975.7s_8584fd7f.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 13/16: slide_g13_t985.7s_b25018b2.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 14/16: slide_g14_t1049.0s_f62d095e.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 15/16: slide_g15_t1049.7s_ff4e1d46.jpg
ä¿å­˜å¹»ç‡ˆç‰‡ 16/16: slide_g16_t1103.0s_be36367b.jpg

å…ƒæ•¸æ“šå·²ä¿å­˜åˆ°: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Mechanisms Linking Adipose Health with Lipid and Glucose Homeostasis/Mechanisms Linking Adipose Health with Lipid and Glucose Homeostasis/Mechanisms Linking Adipose Health with Lipid and Glucose Homeostasis _slides/slides_metadata.json

âœ… æ•ç²æˆåŠŸï¼
   å¹»ç‡ˆç‰‡æ•¸: 16
   åˆ†çµ„æ•¸: 16
   è€—æ™‚: 65.2 ç§’
   è¼¸å‡º: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Mechanisms Linking Adipose Health with Lipid and Glucose Homeostasis/Mechanisms Linking Adipose Health with Lipid and Glucose Homeostasis/Mechanisms Linking Adipose Health with Lipid and Glucose Homeostasis _slides

ç”Ÿæˆ HTML é è¦½...
   é è¦½å·²ç”Ÿæˆ: preview.html

é€²åº¦: 18/28

============================================================
è™•ç†è¦–é »: Mechanistic Insights into Metabolic Dysfunction in the Liver .mp4
è·¯å¾‘: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Mechanistic Insights into Metabolic Dysfunction in the Liver /Mechanistic Insights into Metabolic Dysfunction in the Liver/Mechanistic Insights into Metabolic Dysfunction in the Liver .mp4
============================================================
âš ï¸  å·²å­˜åœ¨å¹»ç‡ˆç‰‡æ–‡ä»¶å¤¾ 'Mechanistic Insights into Metabolic Dysfunction in the Liver _slides'ï¼Œè·³éŽè™•ç†

é€²åº¦: 19/28

============================================================
è™•ç†è¦–é »: Metabolic Mediators of Metabolic Wasting.mp4
è·¯å¾‘: /Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Metabolic Mediators of Metabolic Wasting/Metabolic Mediators of Metabolic Wasting/Metabolic Mediators of Metabolic Wasting.mp4
============================================================
ä½¿ç”¨é€²éšŽæ¨¡å¼æ•ç²å¹»ç‡ˆç‰‡...
ç›¸ä¼¼åº¦é–¾å€¼: 0.8
åˆ†çµ„é–¾å€¼: 0.88
é–‹å§‹åˆ†æžè¦–é »ï¼š/Volumes/WD_BLACK/åœ‹éš›å¹´æœƒ/ADA2025/Metabolic Mediators of Metabolic Wasting/Metabolic Mediators of Metabolic Wasting/Metabolic Mediators of Metabolic Wasting.mp4
ç¸½å¹€æ•¸ï¼š133654, FPSï¼š30.0
ç›¸ä¼¼åº¦é–¾å€¼ï¼š0.8, åˆ†çµ„é–¾å€¼ï¼š0.88

ç¬¬ä¸€éï¼šå¿«é€ŸæŽƒæ...
å¿«é€ŸæŽƒæé€²åº¦ï¼š0.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š0.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š0.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š1.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š1.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š2.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š2.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š3.1%
å¿«é€ŸæŽƒæé€²åº¦ï¼š3.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š4.0%
å¿«é€ŸæŽƒæé€²åº¦ï¼š4.5%
å¿«é€ŸæŽƒæé€²åº¦ï¼š4.9%
å¿«é€ŸæŽƒæé€²åº¦ï¼š5.4%
å¿«é€ŸæŽƒæé€²åº¦ï¼š5.8%
å¿«é€ŸæŽƒæé€²åº¦ï¼š6.3%
å¿«é€ŸæŽƒæé€²åº¦ï¼š6.7%
å¿«é€ŸæŽƒæé€²åº¦ï¼š7.2%
å¿«é€ŸæŽƒæé€²åº¦ï¼š7.6%
å¿«é€ŸæŽƒæé€²åº¦ï¼š8.1%
[h264 @ 0x10d715df0] Invalid NAL unit size (2110 > 253).
[h264 @ 0x10d715df0] missing picture in access unit with size 263
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc784b91: partial file
[h264 @ 0x1321f9160] Invalid NAL unit size (2110 > 253).
[h264 @ 0x1321f9160] Error splitting the input into NAL units.
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc784d01: partial file
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc787024: partial file
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 0, offset 0xc78714a: partial file
[h264 @ 0x10d715df0] Invalid NAL unit size (2110 > 253).
[h264 @ 0x10d715df0] missing picture in access unit with size 263
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc784b91: partial file
[h264 @ 0x1321f9160] Invalid NAL unit size (2110 > 253).
[h264 @ 0x1321f9160] Error splitting the input into NAL units.
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc784d01: partial file
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc787024: partial file
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 0, offset 0xc78714a: partial file
[h264 @ 0x10d715df0] Invalid NAL unit size (2110 > 253).
[h264 @ 0x10d715df0] missing picture in access unit with size 263
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc784b91: partial file
[h264 @ 0x1321f9160] Invalid NAL unit size (2110 > 253).
[h264 @ 0x1321f9160] Error splitting the input into NAL units.
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc784d01: partial file
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc787024: partial file
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 0, offset 0xc78714a: partial file
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc787024: partial file
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 0, offset 0xc78714a: partial file
[h264 @ 0x10d715df0] Invalid NAL unit size (2110 > 253).
[h264 @ 0x10d715df0] missing picture in access unit with size 263
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc784b91: partial file
[h264 @ 0x1321f9160] Invalid NAL unit size (2110 > 253).
[h264 @ 0x1321f9160] Error splitting the input into NAL units.
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc784d01: partial file
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc787024: partial file
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 0, offset 0xc78714a: partial file
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc787024: partial file
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 0, offset 0xc78714a: partial file
[h264 @ 0x10d715df0] Invalid NAL unit size (2110 > 253).
[h264 @ 0x10d715df0] missing picture in access unit with size 263
[h264 @ 0x1321f9160] Invalid NAL unit size (2110 > 253).
[h264 @ 0x1321f9160] Error splitting the input into NAL units.
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc784b91: partial file
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc784d01: partial file
[h264 @ 0x10d715df0] Invalid NAL unit size (3858 > 3439).
[h264 @ 0x10d715df0] missing picture in access unit with size 3449
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc82dd6c: partial file
[h264 @ 0x10d72ad00] Invalid NAL unit size (3858 > 3439).
[h264 @ 0x10d72ad00] Error splitting the input into NAL units.
[h264 @ 0x10d715df0] Invalid NAL unit size (3858 > 3439).
[h264 @ 0x10d715df0] missing picture in access unit with size 3449
[h264 @ 0x10d72ad00] Invalid NAL unit size (3858 > 3439).
[h264 @ 0x10d72ad00] Error splitting the input into NAL units.
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc82dd6c: partial file
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc82deae: partial file
[h264 @ 0x10d715df0] Invalid NAL unit size (3858 > 3439).
[h264 @ 0x10d715df0] missing picture in access unit with size 3449
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc82dd6c: partial file
[h264 @ 0x10d72ad00] Invalid NAL unit size (3858 > 3439).
[h264 @ 0x10d72ad00] Error splitting the input into NAL units.
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc82deae: partial file
[h264 @ 0x10d715df0] Invalid NAL unit size (3858 > 3439).
[h264 @ 0x10d715df0] missing picture in access unit with size 3449
[h264 @ 0x10d72ad00] Invalid NAL unit size (3858 > 3439).
[h264 @ 0x10d72ad00] Error splitting the input into NAL units.
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc82dd6c: partial file
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc82deae: partial file
[h264 @ 0x10d715df0] Invalid NAL unit size (3858 > 3439).
[h264 @ 0x10d715df0] missing picture in access unit with size 3449
[h264 @ 0x10d72ad00] Invalid NAL unit size (3858 > 3439).
[h264 @ 0x10d72ad00] Error splitting the input into NAL units.
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc82dd6c: partial file
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc82deae: partial file
[h264 @ 0x10d715df0] Invalid NAL unit size (3858 > 3439).
[h264 @ 0x10d715df0] missing picture in access unit with size 3449
[h264 @ 0x10d72ad00] Invalid NAL unit size (3858 > 3439).
[h264 @ 0x10d72ad00] Error splitting the input into NAL units.
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc82dd6c: partial file
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc82deae: partial file
[h264 @ 0x10d715df0] Invalid NAL unit size (3662 > 412).
[h264 @ 0x10d715df0] missing picture in access unit with size 422
[h264 @ 0x10d733680] Invalid NAL unit size (3662 > 412).
[h264 @ 0x10d733680] Error splitting the input into NAL units.
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc994a9d: partial file
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc994c12: partial file
[h264 @ 0x10d715df0] Invalid NAL unit size (3662 > 412).
[h264 @ 0x10d715df0] missing picture in access unit with size 422
[h264 @ 0x10d733680] Invalid NAL unit size (3662 > 412).
[h264 @ 0x10d733680] Error splitting the input into NAL units.
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc994a9d: partial file
[mov,mp4,m4a,3gp,3g2,mj2 @ 0x1321f8150] stream 1, offset 0xc994c12: partial file
